F6T.F Fate Therapeutics Inc
- Market cap
- EUR 168M
- P/E
- -
- P/B
- 1.72x
- ROE
- -92.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is F6T.F undervalued?
Graham numberThe Graham number of Fate Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fate Therapeutics Inc fundamental analysis
No fundamental analysis for Fate Therapeutics Inc yet.
Fate Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT…
Full company profileFate Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fate Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.40M | 4.11M | 4.74M | 10.7M | 31.4M | 55.8M | 96.3M | 63.5M | 13.6M | 6.65M | 4.51M |
| Gross Profit | -22.1M | -30.3M | -51.3M | -77.1M | - | - | - | - | - | - | - |
| Operating Income | -32.0M | -42.1M | -67.1M | -101M | -128M | -217M | -308M | -191M | -196M | -148M | -129M |
| EBITDA | - | -40.7M | -63.7M | -94.2M | -170M | -206M | -295M | -172M | -177M | -135M | -117M |
| Net Income | -33.5M | -43.0M | -66.6M | -98.1M | -173M | -212M | -282M | -161M | -186M | -136M | -123M |
| EPS | - | -0.82 | -1.03 | -1.30 | -1.98 | -2.22 | -2.90 | -1.63 | -1.63 | -1.18 | -1.01 |
| Balance Sheet | |||||||||||
| Total Assets | 95.0M | 105M | 213M | 302M | 622M | 921M | 706M | 506M | 441M | 319M | 238M |
| Total Liabilities | 21.9M | 28.1M | 52.6M | 57.5M | 238M | 243M | 222M | 138M | 122M | 112M | 105M |
| Shareholders' Equity | 73.2M | 77.2M | 160M | 245M | 384M | 679M | 484M | 368M | 319M | 207M | 133M |
| Cash & Short-term Investments | 88.6M | 89.0M | 191M | 99.8M | 167M | 134M | 61.3M | 41.9M | 36.1M | 46.6M | 43.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.8M | -36.8M | -38.7M | -83.2M | -39.2M | -163M | -248M | -132M | -123M | -106M | -110M |
| Capital Expenditure | 457K | 1.73M | 2.30M | 7.40M | 4.93M | 50.7M | 35.6M | 6.15M | 730K | 5.95M | 425K |
| Free Cash Flow | - | -38.6M | -41.0M | -90.6M | -44.2M | -214M | -284M | -138M | -124M | -112M | -110M |
| Ratios | |||||||||||
| ROE | -45.7% | -55.6% | -41.5% | -40.1% | -45.1% | -31.3% | -58.2% | -43.7% | -58.4% | -65.8% | -92.3% |
| ROA | -35.2% | -40.8% | -31.3% | -32.5% | -27.9% | -23.0% | -39.9% | -31.8% | -42.3% | -42.7% | -51.5% |
| Net Profit Margin | -760.2% | -1,046.1% | -1,405.0% | -919.0% | -551.6% | -379.9% | -292.5% | -253.3% | -1,366.5% | -2,051.1% | -2,722.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Fate Therapeutics Inc dividends
Fate Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Fate Therapeutics Inc
- Insiders 1.07%
- Institutions 69.91%
- Public & others 29.02%
- Shares outstanding 122M
- Free float 106M
Fate Therapeutics Inc company profile
- Company name
- Fate Therapeutics Inc
- Ticker
- F6T.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 161
- Fiscal year end
- December
- Address
- 12278 Scripps Summit Drive, San Diego, CA, United States, 92131
- Phone
- 858 875 1800
- Website
- fatetherapeutics.com
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics Inc management
10- Dr. Bahram Valamehr M.B.A., Ph.D.President, CEO & Director · born 1977
- Mr. Kamal Adawi M.S., MBACFO & Treasurer · born 1979
- Ms. Cindy R. Tahl J.D.Chief Legal & Compliance Officer and Corporate Secretary · born 1973
- Ms. Jessica FrancisSenior Vice President of Human Resources & Operations
- Dr. Martin HoskingHead of Research
- Dr. Tunde Babalola Ph.D.Senior Vice President of Technical Operations & Quality
- Mr. Ryan DouglasSenior Director of Investor Relations & Business Development
- Mr. Andrew HenrySenior Vice President of Clinical Operations · born 1964
- Dr. Yu Cai J.D., Ph.D.Head of Intellectual Property & Assistant General Counsel
- Mr. James Archie Harrell Jr.Senior Vice President of Market Development & Commercial Operations · born 1970